Preview Mode Links will not work in preview mode

GRACEcast


Aug 26, 2013

Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.